@article{672dc18b4ade48679b6745663ff5797a,
title = "Potential prognostic biomarkers of nima (Never in mitosis, gene a)-related kinase (nek) family members in breast cancer",
abstract = "Breast cancer remains the most common malignant cancer in women, with a staggering incidence of two million cases annually worldwide; therefore, it is crucial to explore novel biomarkers to assess the diagnosis and prognosis of breast cancer patients. NIMA-related kinase (NEK) protein kinase contains 11 family members named NEK1-NEK11, which were discovered from Aspergillus Nidulans; however, the role of NEK family genes for tumor development remains unclear and requires additional study. In the present study, we investigate the prognosis relationships of NEK family genes for breast cancer development, as well as the gene expression signature via the bioinformatics approach. The results of several integrative analyses revealed that most of the NEK family genes are overexpressed in breast cancer. Among these family genes, NEK2/6/8 overexpression had poor prognostic significance in distant metastasis-free survival (DMFS) in breast cancer patients. Meanwhile, NEK2/6 had the highest level of DNA methylation, and the functional enrichment analysis from MetaCore and Gene Set Enrichment Analysis (GSEA) suggested that NEK2 was associated with the cell cycle, G2M checkpoint, DNA repair, E2F, MYC, MTORC1, and interferon-related signaling. Moreover, Tumor Immune Estimation Resource (TIMER) results showed that the transcriptional levels of NEK2 were positively correlated with immune infiltration of B cells and CD4+ T Cell. Collectively, the current study indicated that NEK family genes, especially NEK2 which is involved in immune infiltration, and may serve as prognosis biomarkers for breast cancer progression.",
keywords = "Bioinformatics, Biomarker, Breast cancer, Functional enrichment analysis, Immune infiltration, Immune microenvironment, NEK family genes, Prognosis",
author = "Gangga Anuraga and Wang, {Wei Jan} and Phan, {Nam Nhut} and Ton, {Nu Thuy An} and Ta, {Hoang Dang Khoa} and Prayugo, {Fidelia Berenice} and Xuan, {Do Thi Minh} and Ku, {Su Chi} and Wu, {Yung Fu} and Vivin Andriani and Muhammad Athoillah and Lee, {Kuen Haur} and Wang, {Chih Yang}",
note = "Funding Information: Funding: The study was supported by grants from Taipei Medical University (grant TMU-108-AE1-B16 to C.-Y.W.), and the Ministry of Science and Technology (MOST) of Taiwan (MOST109-2320-B-038-009-MY2 to C-Y.W. and MOST-109-2320-B-039 -003-MY2 and MOST-110-2320-B-039-068 to W-J.W.), China Medical University (CMU109-MF-55 to W-J.W.), the Ministry Health and Welfare Surcharge of Education Tobacco Products of Taiwan (Wan-Fang Hospital, Chi-Mei Medical Center, and Hualien Tzu-Chi Hospital Joint Cancer Center Grant-Focus on Colon Cancer Research; grant no.: MOHW110-TDU-B-212-144020, awarded to K.-H.L.), Ministry of Education of Taiwan (grant no.: DP2-110-21121-03-C-03-03), and the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = nov,
doi = "10.3390/jpm11111089",
language = "English",
volume = "11",
journal = "Journal of Personalized Medicine",
issn = "2075-4426",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",
}
